NYLIM
PTCT icon

New York Life Investment Management’s PTC Therapeutics PTCT Stock Holding History

New York Life Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,753
Closed -$371K – 1208
2024
Q1 		$371K Buy
+12,753
New +$357K ﹤0.01% 958
2023
Q3 		– Sell
-8,508
Closed -$346K – 1313
2023
Q2 		$346K Sell
8,508
-1,295
-13% -$63.4K ﹤0.01% 1171
2023
Q1 		$475K Buy
+9,803
New +$448K 0.01% 1009

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York Life Investment Management's PTCT Position: Q2 2024 in Review

New York Life Investment Management sold out of PTC Therapeutics (PTCT) in Q2 2024, closing a stake of 12,753 shares — an estimated $371K sold.

New York Life Investment Management first reported a position in PTCT in Q1 2023 and held it in 3 quarters. The position peaked at $475K in Q1 2023. 199 funds tracked by Wall St. Rank hold PTCT as of Q2 2024.

  • New York Life Investment Management reported no remaining PTC Therapeutics position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 12,753 PTC Therapeutics shares in Q2 2024, an estimated $371K.
  • New York Life Investment Management first reported a position in PTC Therapeutics in Q1 2023 and held it in 3 quarters.
  • New York Life Investment Management's PTC Therapeutics position peaked at $475K in Q1 2023.
  • 199 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.